What is enGene Holdings Financial Strength?
enGene Holdings has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
enGene Holdings did not have earnings to cover the interest expense.
As of today, enGene Holdings's Altman Z-Score is 0.00.
Competitive Comparison of enGene Holdings's Financial Strength
For the Biotechnology subindustry, enGene Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Holdings's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where enGene Holdings's Financial Strength falls into.
enGene Holdings Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
enGene Holdings's Interest Expense for the
months ended in Jan. 2024 was $-0.56 Mil. Its Operating Income for the
months ended in Jan. 2024 was $-10.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $24.13 Mil.
enGene Holdings's Interest Coverage for the quarter that ended in Jan. 2024 is
| enGene Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
enGene Holdings's Debt to Revenue Ratio for the quarter that ended in Jan. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
enGene Holdings has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings (enGene Holdings) Business Description
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
| Richard M Glickman |
director |
C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
| Jason David Hanson |
director, officer: Chief Executive Officer |
8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463 |
| Lumira Capital Investment Management Inc. |
10 percent owner |
141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
| Richard Paul Bryce |
officer: Chief Medical Officer |
C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
| Fonds De Solidarite Des Travailleurs Du Quebec |
10 percent owner |
545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
| Gerald A Brunk |
director |
C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142 |
| Jasper Bos |
director |
BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102 |
| Grassin Alexandre Jean-rene Erwan |
officer: Int. Chief Financial Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Anthony Tzeyew Cheung |
officer: Chief Technology Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Alexander Julian Nichols |
officer: Pres. & Chief Operating Ofc. |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| James Crowley Sullivan |
officer: Chief Scientific Officer |
7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
| Forbion Growth Sponsor Feac I B.v. |
10 percent owner |
GOOIMEER 2 35,, NAARDEN P7 1411DC |
| Forbion Growth Opportunities Fund I Cooperatief U.a. |
10 percent owner |
GOOIMEER 235, 1411 DC, NAARDEN P7 00000 |
| Forbion Growth Management B.v. |
10 percent owner |
C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807 |
enGene Holdings (enGene Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENGN has been successfully added to your